Klinisch orientierter Schwerpunkt
FB 04 - Universitätsmedizin / Johannes Gutenberg-Universität Mainz
Schulte, Christina; Gauler, Thomas; Poettgen, Christoph et al.
Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE)INTERNATIONAL JOURNAL OF CANCER. Bd. 156. H. 1. 2025 S. 154-163
Schmidt, M
Systemtherapie des HER2-low fortgeschrittenen MammakarzinomsLeading Opinions Gynäkologie & Geburtshilfe. Bd. 1/2025. 2025 S. 6-7
Gerlach, Christina; Weber, Martin; Schmidtmann, Irene
The 'Surprise' Question in Haemato-Oncology: The Estimating Physician and Time to Death Reduce the Prognostic Uncertainty-An Observational StudyCANCERS. Bd. 17. H. 8. 2025
Mora, Jaume; Chan, Godfrey C. F.; Morgenstern, Daniel A. et al.
The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trialNATURE COMMUNICATIONS. Bd. 16. H. 1. 2025
Seidmann, Larissa; Wingerter, Arthur; Metzig, Marie Oliver et al.
The Chimeric Antigen Receptor T Cell Target Claudin 6 Is a Marker for Early Organ-Specific Epithelial Progenitors and Is Expressed in Some Pediatric Solid Tumor EntitiesCANCERS. Bd. 17. H. 6. 2025
Kuehn, Michael W. M.; Pemmaraju, Naveen; Heidel, Florian H.
The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasmsLEUKEMIA. Bd. 39. H. 8. 2025 S. 1824-1837
Strampfer, Lisa; Ellebrecht, Nils; Hasenburg, Annette et al.
The financial burden of fertility preservation: does the german cryo-guideline provide relief for oncology patients?PRAVENTION UND GESUNDHEITSFORDERUNG. 2025
Abou Dalle, Iman; Galimard, Jacques-Emmanuel; Poire, Xavier et al.
The impact of <i>DNMT3A</i> mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutationsBONE MARROW TRANSPLANTATION. 2025
Herold, Stephanie; Schmidt, Christian; Visco, Carlo et al.
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatmentBMC CANCER. Bd. 25. H. 1. 2025
Schwab, Roxana; Evangelos, Papanikolaou; Boutas, Ioannis et al.
The Role Of Prehabilitation In ERAS For Gynecologic Oncology In GermanyINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Bd. 35. H. 2. 2025 S. 52-52